About Us
We have the expertise you have been looking for
In 2022, Dr. Tina Bland stepped away from a successful corporate career of over 20 years to establish Grand Strand Clinical Trial Services. At GSCTS, we aim to bridge the gap between the drug development teams in Pharma and Biotech companies and the investigative study sites in hospitals and clinics worldwide by providing medical writing/essential document development, clinical operations team training and oversight, and general scientific consulting. In addition, Grand Strand Clinical Trial Services advocates for and provides resourcing support to investigative sites in community hospitals in an effort to bring clinical trials to rural areas.
Tina Bland, PhD
Founder
For over twenty years, Dr. Tina Bland has been highly involved in pharmaceutical drug development, clinical trial execution and laboratory and clinical operations. She has substantial professional experience in essential document development inclusive of clinical trial protocols – all phases, informed consent forms/patient facing materials, clinical study reports, eCRF design and regulatory briefing documents. Her objectives are to leverage these experiences in client projects to facilitate and expedite transition from the preclinical space to and through clinical development and marketing authorization; and, to advocate for and provide resourcing support to investigative sites in the community hospital setting.
Amanda Ellis
Consulting Partner
Amanda is an accomplished management professional with ~15 years’ experience in commercial and business operations management, clinical trial strategy, feasibility and planning, strategic partnerships, customer relationship management, proposal development, budget negotiation, and vendor procurement and management within the clinical research, biotech, and pharmaceutical sectors. Amanda has a solid foundation in clinical research, with a Master's and Bachelor's degree in Clinical Research and Product Development and Program Management.
Our mission is to facilitate the development of life-changing treatments while expanding the reach of clinical trials to increase enrollment efficiency and advocating for equitable access to clinical trials, particularly in underserved communities.
